NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Forecast & News

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.99) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.09. The specialty pharmaceutical company earned $13.93 million during the quarter, compared to analyst estimates of $14.36 million. Adamas Pharmaceuticals had a negative net margin of 215.09% and a negative return on equity of 205.30%. View Adamas Pharmaceuticals' Earnings History.

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Adamas Pharmaceuticals.

Adamas Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Wednesday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.6-54.6 million, compared to the consensus revenue estimate of $53.65 million.

10 analysts have issued 1-year price objectives for Adamas Pharmaceuticals' shares. Their forecasts range from $5.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' share price to reach $15.67 in the next year. This suggests a possible upside of 197.3% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

Media stories about ADMS stock have trended somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Adamas Pharmaceuticals.

Adamas Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,380,000 shares, an increase of 28.6% from the December 31st total of 1,850,000 shares. Based on an average daily volume of 641,000 shares, the short-interest ratio is presently 3.7 days. Approximately 10.7% of the company's stock are short sold. View Adamas Pharmaceuticals' Current Options Chain.

Some companies that are related to Adamas Pharmaceuticals include AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Kura Oncology (KURA), MacroGenics (MGNX), Milestone Pharmaceuticals (MIST), Atreca (BCEL), Neoleukin Therapeutics (NLTX), BioDelivery Sciences International (BDSI), Prothena (PRTA), Molecular Templates (MTEM), Axovant Sciences (AXON) and CytoDyn (CYDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sangamo Therapeutics (SGMO), Abeona Therapeutics (ABEO), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Ardelyx (ARDX), Cara Therapeutics (CARA), Century Aluminum (CENX) and Omeros (OMER).

Adamas Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Deltec Asset Management LLC (1.43%) and California Public Employees Retirement System (0.06%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals.

ADMS stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes. View Insider Buying and Selling for Adamas Pharmaceuticals.

ADMS stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. View Insider Buying and Selling for Adamas Pharmaceuticals.

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMS stock can currently be purchased for approximately $5.27.

Adamas Pharmaceuticals has a market capitalization of $146.81 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]